Tokuda Yutaka相关文献与解析，生知库 | 链接生命科学的每一步

Correction to: Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

更正：N·SAS-BC 01 试验中对切除的 I-IIIA 期、高危、淋巴结阴性浸润性乳腺癌的核分级系统进行验证

Tsuda, Hitoshi; Kurosumi, Masafumi; Akiyama, Futoshi; Ohno, Shinji; Saji, Shigehira; Masuda, Norikazu; Shimomura, Akihiko; Sato, Nobuaki; Takao, Shintaro; Ohsumi, Shozo; Tokuda, Yutaka; Inaji, Hideo; Watanabe, Toru

肿瘤

Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

在 N·SAS-BC 01 试验中验证用于切除的 I-IIIA 期、高危、淋巴结阴性浸润性乳腺癌的核分级系统

期刊:Breast Cancer

影响因子:

doi:10.1007/s12282-022-01350-4

HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice

将乳腺癌淋巴细胞移植到 hu-PBL hIL-4 NOG 小鼠体内，诱导 HER2 抗原特异性体液免疫反应

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-021-92311-y

Ohno, Yusuke; Ohshima, Shino; Miyamoto, Asuka; Kametani, Fuyuki; Ito, Ryoji; Tsuda, Banri; Kasama, Yukie; Nakada, Shunsuke; Kashiwagi, Hirofumi; Seki, Toshiro; Yasuda, Atsushi; Ando, Kiyoshi; Ito, Mamoru; Tokuda, Yutaka; Kametani, Yoshie

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

两项前瞻性随机对照试验比较了口服替加氟-尿嘧啶与 CMF 的疗效，研究了病理因素与患者长期预后之间的关系（N·SAS-BC 01 试验和 CUBC 试验）。

期刊:Breast Cancer Research and Treatment

影响因子:3

doi:10.1007/s10549-020-06018-1

Ohno, Shinji; Saji, Shigehira; Masuda, Norikazu; Tsuda, Hitoshi; Akiyama, Futoshi; Kurosumi, Masafumi; Shimomura, Akihiko; Sato, Nobuaki; Takao, Shintaro; Ohsumi, Shozo; Tokuda, Yutaka; Inaji, Hideo; Watanabe, Toru; Ohashi, Yasuo

UBC

发表日期：2021

文献求助收藏

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

一项多中心、随机、开放标签、平行组、III期非劣效性研究，比较NK105和紫杉醇在转移性或复发性乳腺癌患者中的疗效。

期刊:British Journal of Cancer

影响因子:6.8

doi:10.1038/s41416-019-0391-z

Fujiwara, Yasuhiro; Mukai, Hirofumi; Saeki, Toshiaki; Ro, Jungsil; Lin, Yung-Chang; Nagai, Shigenori E; Lee, Keun Seok; Watanabe, Junichiro; Ohtani, Shoichiro; Kim, Sung Bae; Kuroi, Katsumasa; Tsugawa, Koichiro; Tokuda, Yutaka; Iwata, Hiroji; Park, Yeon Hee; Yang, Youngsen; Nambu, Yoshihiro

Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors

人源化小鼠作为肽疫苗和免疫检查点抑制剂的有效评价系统

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms20246337

Kametani, Yoshie; Ohno, Yusuke; Ohshima, Shino; Tsuda, Banri; Yasuda, Atsushi; Seki, Toshiro; Ito, Ryoji; Tokuda, Yutaka

B-cell populations are expanded in breast cancer patients compared with healthy controls.

与健康对照组相比，乳腺癌患者的B细胞数量增加

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-017-0824-6

Tsuda Banri, Miyamoto Asuka, Yokoyama Kozue, Ogiya Rin, Oshitanai Risa, Terao Mayako, Morioka Toru, Niikura Naoki, Okamura Takuho, Miyako Hirohito, Saito Yuki, Suzuki Yasuhiro, Kametani Yoshie, Tokuda Yutaka

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer

一项随机II期研究评估了nab-紫杉醇作为HER2阴性转移性乳腺癌患者一线化疗的疗效

期刊:Cancer Science

影响因子:4.3

doi:10.1111/cas.13221

Tamura, Kenji; Inoue, Kenichi; Masuda, Norikazu; Takao, Shintaro; Kashiwaba, Masahiro; Tokuda, Yutaka; Iwata, Hiroji; Yamamoto, Naohito; Aogi, Kenjiro; Saeki, Toshiaki; Nakayama, Takahiro; Sato, Nobuaki; Toyama, Tatsuya; Ishida, Takanori; Arioka, Hitoshi; Saito, Mitsue; Ohno, Shinji; Yamauchi, Hideko; Yamada, Kimito; Watanabe, Junichiro; Ishiguro, Hiroshi; Fujiwara, Yasuhiro

NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination

NOG-hIL-4-Tg 是一种新型人源化小鼠模型，可通过肽疫苗接种产生肿瘤抗原特异性 IgG 抗体。

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0179239

Kametani, Yoshie; Katano, Ikumi; Miyamoto, Asuka; Kikuchi, Yusuke; Ito, Ryoji; Muguruma, Yukari; Tsuda, Banri; Habu, Sonoko; Tokuda, Yutaka; Ando, Kiyoshi; Ito, Mamoru

Electrically Induced Liquid Metal Droplet Bouncing

电致液态金属液滴弹跳

Correction to: Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

更正：N·SAS-BC 01 试验中对切除的 I-IIIA 期、高危、淋巴结阴性浸润性乳腺癌的核分级系统进行验证

Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

在 N·SAS-BC 01 试验中验证用于切除的 I-IIIA 期、高危、淋巴结阴性浸润性乳腺癌的核分级系统

HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice

将乳腺癌淋巴细胞移植到 hu-PBL hIL-4 NOG 小鼠体内，诱导 HER2 抗原特异性体液免疫反应

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

两项前瞻性随机对照试验比较了口服替加氟-尿嘧啶与 CMF 的疗效，研究了病理因素与患者长期预后之间的关系（N·SAS-BC 01 试验和 CUBC 试验）。

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

一项多中心、随机、开放标签、平行组、III期非劣效性研究，比较NK105和紫杉醇在转移性或复发性乳腺癌患者中的疗效。

Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors

人源化小鼠作为肽疫苗和免疫检查点抑制剂的有效评价系统

B-cell populations are expanded in breast cancer patients compared with healthy controls.

与健康对照组相比，乳腺癌患者的B细胞数量增加

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer

一项随机II期研究评估了nab-紫杉醇作为HER2阴性转移性乳腺癌患者一线化疗的疗效

NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination

NOG-hIL-4-Tg 是一种新型人源化小鼠模型，可通过肽疫苗接种产生肿瘤抗原特异性 IgG 抗体。